21,423 results match your criteria cirrhotic liver


Rifaximin reduces gut-derived inflammation and mucin degradation in cirrhosis and encephalopathy: RIFSYS randomised controlled trial.

J Hepatol 2021 Sep 24. Epub 2021 Sep 24.

Institute of Liver Studies, School of Immunology and Microbial Sciences, Faculty of Life Sciences and Medicine, King's College London, 125 Coldharbour Lane, London SE5 9NU, UK; Institute of Liver Studies, King's College Hospital NHS Foundation Trust, Denmark Hill, London, SE5 9RS, UK. Electronic address:

Background: Rifaximin is efficacious in the prevention of recurrent hepatic encephalopathy (HE) but its mechanism of action remains unclear. We postulated that rifaximin reduces gut microbiota-derived endotoxemia and systemic inflammation, a known driver of HE.

Design: A randomised placebo-controlled double-blind mechanistic study of rifaximin versus placebo was performed in cirrhotic patients with HE. Read More

View Article and Full-Text PDF
September 2021

Reappraisal of the Role of Ascitic Fluid Adenosine Deaminase for the Diagnosis of Peritoneal Tuberculosis in Cirrhosis.

Korean J Gastroenterol 2021 Sep;78(3):168-176

Department of Gastroenterology, G. B. Pant Institute of Postgraduate Medical Education and Research (GIPMER), New Delhi, India.

Backgrounds/aims: Although peritoneal tuberculosis (TB) is one of the important differential diagnoses among cirrhotic patients with ascites, a peritoneal biopsy is not always available. High ascitic fluid adenosine deaminase (ADA) has been indicative of peritoneal TB. On the other hand, studies to assess its diagnostic utility based on the confirmation of peritoneal biopsy in cirrhotic patients are scarce. Read More

View Article and Full-Text PDF
September 2021

[Diagnosis and Management of Esophageal and Gastric Variceal Bleeding: Focused on 2019 KASL Clinical Practice Guidelines for Liver Cirrhosis].

Korean J Gastroenterol 2021 Sep;78(3):152-160

Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea.

Varices are a frequent complication of liver cirrhosis and a major cause of mortality in patients with liver cirrhosis. Patients with decompensated cirrhosis complications have a poor prognosis and require careful management. Portal hypertension is the most common complication of liver cirrhosis, which is the key determinant for varices development. Read More

View Article and Full-Text PDF
September 2021

Liver-to-Spleen Volume Ratio Automatically Measured on CT Predicts Decompensation in Patients with B Viral Compensated Cirrhosis.

Korean J Radiol 2021 Aug 31. Epub 2021 Aug 31.

Department of Radiology and Research Institute of Radiology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea.

Objective: Although the liver-to-spleen volume ratio (LSVR) based on CT reflects portal hypertension, its prognostic role in cirrhotic patients has not been proven. We evaluated the utility of LSVR, automatically measured from CT images using a deep learning algorithm, as a predictor of hepatic decompensation and transplantation-free survival in patients with hepatitis B viral (HBV)-compensated cirrhosis.

Materials And Methods: A deep learning algorithm was used to measure the LSVR in a cohort of 1027 consecutive patients (mean age, 50. Read More

View Article and Full-Text PDF

Renormalization of Thalamic Sub-Regional Functional Connectivity Contributes to Improvement of Cognitive Function after Liver Transplantation in Cirrhotic Patients with Overt Hepatic Encephalopathy.

Korean J Radiol 2021 Aug 31. Epub 2021 Aug 31.

Department of Radiology, Tianjin First Central Hospital, Tianjin, China.

Objective: The role of preoperative overt hepatic encephalopathy (OHE) in the neurophysiological mechanism of cognitive improvement after liver transplantation (LT) remains elusive. This study aimed to explore changes in sub-regional thalamic functional connectivity (FC) after LT and their relationship with neuropsychological improvement using resting-state functional MRI (rs-fMRI) data in cirrhotic patients with and without a history of OHE.

Materials And Methods: A total of 51 cirrhotic patients, divided into the OHE group (n = 21) and no-OHE group (n = 30), and 30 healthy controls were enrolled in this prospective study. Read More

View Article and Full-Text PDF

Multicenter study on recent portal venous system thrombosis associated with cytomegalovirus disease.

J Hepatol 2021 Sep 23. Epub 2021 Sep 23.

Université de Paris, AP-HP, Hôpital Beaujon, Service d'Hépatologie, DMU DIGEST, Centre de Référence des Maladies Vasculaires du Foie, FILFOIE, ERN RARE-LIVER, Centre de recherche sur l'inflammation, Inserm, UMR 1149. Paris, France. Electronic address:

Background And Aims: Recent non-malignant non-cirrhotic portal venous system thrombosis (PVT) is a rare condition. Among risk factors for PVT, cytomegalovirus (CMV) disease is usually listed based on few reported cases. The aim of this study was to determine characteristics and outcome of patients with PVT associated with CMV disease. Read More

View Article and Full-Text PDF
September 2021

Non-malignant portal vein thrombi in patients with cirrhosis consist of intimal fibrosis with or without a fibrin-rich thrombus.

Hepatology 2021 Sep 24. Epub 2021 Sep 24.

Surgical Research Laboratory, Department of Surgery, University Medical Center Groningen, Groningen, the Netherlands.

Background And Aim: Portal vein thrombosis (PVT) is a common complication of cirrhosis. The exact pathophysiology remains largely unknown and treatment with anticoagulants does not lead to recanalization of the portal vein in all patients. A better insight in the structure and composition of portal vein thrombi may assist in developing new strategies for the prevention and treatment of PVT. Read More

View Article and Full-Text PDF
September 2021

Multimodal and systemic therapy with cabozantinib for treatment of recurrent hepatocellular carcinoma after liver transplantation: A case report with long term follow-up outcomes.

Medicine (Baltimore) 2021 Sep;100(38):e27082

Department of Internal Medicine I, University Hospital Bonn, Germany.

Rationale: Recurrence of hepatocellular carcinoma (HCC) after liver transplantation (LT) remains a major therapeutic challenge. In recent years, new molecular-targeted therapies, such as cabozantinib, have been approved for the treatment of advanced HCC. However, clinical experience with these new drugs in the treatment of HCC in the LT setting is very limited. Read More

View Article and Full-Text PDF
September 2021

Hepatocyte Nuclear Factor 4 alpha 2 Messenger RNA Reprograms Liver-Enriched Transcription Factors and Functional Proteins in End-Stage Cirrhotic Human Hepatocytes.

Hepatol Commun 2021 Jul 1. Epub 2021 Jul 1.

Department of Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.

The only definitive therapy for end-stage liver disease is whole-organ transplantation. The success of this intervention is severely limited by the complexity of the surgery, the cost of patient care, the need for long-term immunosuppression, and the shortage of donor organs. In rodents and humans, end-stage degeneration of hepatocyte function is associated with disruption of the liver-specific transcriptional network and a nearly complete loss of promoter P1-driven hepatocyte nuclear factor 4-alpha (P1-HNF4α) activity. Read More

View Article and Full-Text PDF

Using machine learning methods to predict hepatic encephalopathy in cirrhotic patients with unbalanced data.

Comput Methods Programs Biomed 2021 Sep 16;211:106420. Epub 2021 Sep 16.

Department of Health Statistics, Shanxi Medical University, Taiyuan, China. Electronic address:

Objective: Hepatic encephalopathy (HE) is among the most common complications of cirrhosis. Data for cirrhosis with HE is typically unbalanced. Traditional statistical methods and machine learning algorithms thus cannot identify a few classes. Read More

View Article and Full-Text PDF
September 2021

infection in liver cirrhosis patients: A population-based study in United States.

World J Hepatol 2021 Aug;13(8):926-938

Department of Gastroenterology, Staten Island University Hospital, Staten Island, NY 10305, United States.

Background: (formerly ) infection (CDI) is an increasingly frequent cause of morbidity and mortality in hospitalized patients. Multiple risk factors are documented in the literature that includes, but are not limited to, antibiotics use, advanced age, and gastric acid suppression. Several epidemiological studies have reported an increased incidence of CDI in advanced liver disease patients. Read More

View Article and Full-Text PDF

Anticoagulation Therapy for Portal Vein Thrombosis in Patients with Cirrhosis in a Tertiary Center Experience.

J Gastrointestin Liver Dis 2021 Sep 21;30(3):374-379. Epub 2021 Sep 21.

Carol Davila University of Medicine and Pharmacy, Faculty of Medicine, Bucharest; Centre for Digestive Diseases and Liver Transplantation, Fundeni Clinical Institute, Bucharest, Romania.

Background And Aims: The evidence regarding the use of anticoagulant (AC) agents in portal vein thrombosis (PVT) is increasing and, most patients undergo chronic treatment with low molecular weight heparin (LMWH) or vitamin K antagonists (VKA). Nevertheless, there are no clear data about who should receive antithrombotic therapy, when to initiate it, how long and what dose should be used for this set of patients. The aim of the study was to assess the outcome of patients with cirrhosis and portal vein thrombosis who received AC therapy, in terms of thrombus regression, bleeding events and survival rates. Read More

View Article and Full-Text PDF
September 2021

Upper Gastrointestinal Bleeding in a Patient with Liver Cirrhosis: Gastroesophageal Varices Are not Always to Blame.

J Gastrointestin Liver Dis 2021 Sep 21;30(3):323. Epub 2021 Sep 21.

Gastroenterology Department, Centro Hospitalar de São João, Porto, Portugal.

A 45-year-old male with active alcoholism and liver cirrhosis was brought to emergency room with hypovolemic shock in context of diarrhea and melena. He presented with hemodynamic instability, hyperlactatemia and anemia. Aggressive supportive therapy with vasopressor support, packed red blood cell transfusion and intra-venous proton pump inhibitor was started. Read More

View Article and Full-Text PDF
September 2021

Letter to the editor on "risk factors for hepatic insufficiency after major hepatectomy in non-cirrhotic patients".

Asian J Surg 2021 Sep 18. Epub 2021 Sep 18.

The First Affiliated Hospital of Harbin Medical University, HeiLongJiang, China. Electronic address:

It is very necessary for patients with liver cancer to reasonably apply the prediction method of liver failure after hepatectomy before liver surgery. Liver surgeons can benefit greatly from clinical activities. Read More

View Article and Full-Text PDF
September 2021

Surveillance for hepatocellular carcinoma in people of African ancestry with HIV and Hepatitis B.

Int J STD AIDS 2021 Sep 21:9564624211042828. Epub 2021 Sep 21.

111990King's College Hospital NHS Foundation Trust, London, UK.

Current guidelines recommend six-monthly ultrasound surveillance for hepatocellular carcinoma (HCC) in high risk, non-cirrhotic people with HIV and hepatitis B co-infection (HBV). African or Asian ethnicity is considered a risk factor for the development of HCC. Risk stratification scores for HCC have been generated in HBV mono-infected Caucasian and Asian populations, however they not been validated in people with HIV or those of African ancestry. Read More

View Article and Full-Text PDF
September 2021

The improvement in body composition including subcutaneous and visceral fat reduces ammonia and hepatic encephalopathy after transjugular intrahepatic portosystemic shunt.

Liver Int 2021 Sep 20. Epub 2021 Sep 20.

Department of Translational and Precision Medicine, "Sapienza" University of Rome, Rome, Italy.

Background: Sarcopenia and myosteatosis have been associated to a poor prognosis of cirrhosis and to a higher incidence of hepatic encephalopathy (HE). The prognostic implications of visceral and subcutaneous adiposity are less known.

Aim: to evaluate the modifications of visceral and subcutaneous adipose tissue after TIPS and to investigate their relationships with the modification of muscle mass and with the incidence of post-TIPS HE. Read More

View Article and Full-Text PDF
September 2021

Hepatocellular Carcinoma.

Am J Clin Pathol 2021 Sep 20. Epub 2021 Sep 20.

Department of Pathology, New Haven, CT, USA.

Objectives: The pathologic differences between hepatocellular carcinoma (HCC) arising in noncirrhotic and cirrhotic livers have not been well studied.

Methods: We performed a retrospective analysis of 378 HCC cases (95 in noncirrhotic, 283 in cirrhotic livers) from pathology archives (2010-2017).

Results: Patients without cirrhosis were more likely to have hepatitis B (13. Read More

View Article and Full-Text PDF
September 2021

infection and peptic ulcer disease in cirrhotic patients: An updated meta-analysis.

World J Clin Cases 2021 Aug;9(24):7073-7084

Department of Gastroenterology and Hepatology, Beijing You'an Hospital Affiliated with Capital Medical University, Beijing 100069, China.

Background: Peptic ulcer (PU) is more prevalent in patients with liver cirrhosis. The role of () infection in the pathogenesis of PU in patients with cirrhosis is still not elucidated.

Aim: To perform a meta-analysis on the prevalence of infection and PU and their association in liver cirrhosis patients. Read More

View Article and Full-Text PDF

Efficacy and Safety of Treatments for Patients With Portal Hypertension and Cirrhosis: A Systematic Review and Bayesian Network Meta-Analysis.

Front Med (Lausanne) 2021 3;8:712918. Epub 2021 Sep 3.

State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.

Viral hepatitis are one of the main causes of liver cirrhosis. The treatment of portal hypertension caused by liver cirrhosis is difficult and diverse, and the therapeutic effect is unknown. Bayesian network meta-analysis was performed to compare the efficacy and safety of treatments for patients with portal hypertension and cirrhosis, including a transjugular intrahepatic portosystemic shunt (TIPS), endoscopic therapy, surgical therapy and medications. Read More

View Article and Full-Text PDF
September 2021

Sofosbuvir/Velpatasvir - A Promising Treatment for Chronic Hepatitis C Virus Infection.

Cureus 2021 Aug 16;13(8):e17237. Epub 2021 Aug 16.

Internal Medicine, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA.

Hepatitis C virus (HCV) infection is a disease that affects millions of people worldwide and has an enormous global public health impact. Chronic HCV is a long-term infection that goes unnoticed until the virus destroys the liver enough to induce liver disease symptoms. The inadequate and poorly tolerated treatment contributes to the burden of chronic HCV. Read More

View Article and Full-Text PDF

The Effect of the Platelet Administration for the Patients with Liver Dysfunction after Liver Resection: Preliminary Clinical Trial.

Case Rep Gastrointest Med 2021 8;2021:9948854. Epub 2021 Sep 8.

Department of Gastrointestinal and Hepato-Biliary-Pancreatic Surgery, Faculty of Medicine, University of Tsukuba, Tsukuba 305-8575, Japan.

The aim of this study is to investigate the effect of platelet on the improvement of deteriorated liver function after liver resection. Six patients with hepatocellular carcinoma and liver cirrhosis have received the partial hepatectomy in the institution. Their Child-Pugh grade was B, and platelet count was below 7,000/l. Read More

View Article and Full-Text PDF
September 2021

Management of Flood syndrome: What can we do better?

World J Gastroenterol 2021 Aug;27(32):5297-5305

Clinic of Gastroenterology, Nephrourology and Surgery, Centre of Hepatology, Gastroenterology and Dietetics, Institute of Clinical Medicine, Vilnius University, Vilnius 03104, Lithuania.

Approximately 20% of cirrhotic patients with ascites develop umbilical herniation. These patients usually suffer from multisystemic complications of cirrhosis, have a significantly higher risk of infection, and require accurate surveillance- especially in the context of the coronavirus disease 2019 pandemic. The rupture of an umbilical hernia, is an uncommon, life-threatening complication of large-volume ascites and end-stage liver disease resulting in spontaneous paracentesis, also known as Flood syndrome. Read More

View Article and Full-Text PDF

p70 ribosomal protein S6 kinase is a checkpoint of human hepatic stellate cell activation and liver fibrosis in mice.

Cell Mol Gastroenterol Hepatol 2021 Sep 16. Epub 2021 Sep 16.

Department of Medicine II, University Hospital, LMU Munich, Germany; Liver Center, University Hospital, LMU Munich, Germany.

Background & Aims: Progression of chronic liver disease (CLD) to liver cirrhosis and liver cancer is a major global cause of morbidity and mortality. Treatment options capable of inhibiting progression of liver fibrosis when aetiological treatment of CLD is not available or fails, have yet to be established. We investigated the role of serine/threonine kinase p70S6K (p70 ribosomal protein S6 kinase) as checkpoint of fibrogenesis in hepatic stellate cells (HSC) and as target for the treatment of liver fibrosis. Read More

View Article and Full-Text PDF
September 2021

Chronic intravascular coagulation in liver cirrhosis predicts a high hemorrhagic risk.

Eur Rev Med Pharmacol Sci 2021 Sep;25(17):5518-5524

Hemostasis and Thrombosis Unit, Department of Medical Science and Public Health, University of Cagliari, Cagliari, Italy.

Objective: In liver cirrhosis, a complex coagulopathy does exist. The aim was to investigate whether a possible chronic consumption coagulopathy is the underlying phenomenon of the disease.

Patients And Methods: We measured endogenous thrombin generation with and without thrombomodulin (ETP ratio) along with D-Dimer in a group of consecutive 282 cirrhotic patients. Read More

View Article and Full-Text PDF
September 2021

Plasma YAP1 predicts esophageal varices and the risk of variceal bleeding in liver cirrhosis.

Biomark Med 2021 Sep 17. Epub 2021 Sep 17.

Department of Traditional & Western Medical Hepatology, Third Hospital of Hebei Medical University, Hebei Key Laboratory of Mechanism of Liver Fibrosis in Chronic Liver Diseases, Shijiazhuang, 050051, China.

To explore the predictive value of plasma YAP1 for esophageal varices (EV) and high-risk EV (HRV) in patients with liver cirrhosis. A total of 208 patients with liver cirrhosis were enrolled and categorized into four groups. Correlation analysis, logistic regression analysis and receiver operating characteristic curve analysis were performed to evaluate the diagnostic performance of plasma YAP1 for EV and HRV. Read More

View Article and Full-Text PDF
September 2021

The impact of liver fibrosis on microvascular invasion and prognosis of hepatocellular carcinoma with a solitary nodule: a Surveillance, Epidemiology, and End Results (SEER) database analysis.

Ann Transl Med 2021 Aug;9(16):1310

Department of Hepatobiliary Surgery and Liver Transplantation Center, The Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai, China.

Background: The pathogenesis of non-cirrhotic hepatocellular carcinoma (HCC) with a high recurrence remains controversial, while microvascular invasion (MVI) is highly suggestive of tumor recurrence. This study aimed to investigate the effects of liver fibrosis on MVI and prognosis in HCC.

Methods: Based on the data of HCC in the Surveillance, Epidemiology, and End Results (SEER) database [2004-2015], multivariate logistic regression was used for correlation analysis. Read More

View Article and Full-Text PDF

Baseline Neutrophil-to-Lymphocyte Ratio Is Independently Associated With 90-Day Transplant-Free Mortality in Patients With Cirrhosis.

Front Med (Lausanne) 2021 31;8:726950. Epub 2021 Aug 31.

Department of Infectious Diseases, Institute of Infection and Immunology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.

Patients with cirrhosis have an increased risk of short-term mortality, however, few studies quantify the association between neutrophil-to-lymphocyte ratio (NLR) and 90-day transplant-free mortality in cirrhotic patients. We prospectively analyzed 3,970 patients with chronic liver diseases from two multicenter cohorts in China (January 2015 to December 2016 and July 2018 to January 2019). Restricted cubic splines (RCS) were used to analyze the relation of NLR and all-causes 90-day transplant-free mortality in cirrhosis. Read More

View Article and Full-Text PDF

Direct-acting antiviral regimens in Egyptian patients with chronic hepatitis C virus infection: A real-world single-center experience.

Arab J Gastroenterol 2021 Sep 13. Epub 2021 Sep 13.

Department of Pediatrics and Clinical Research Center, Faculty of Medicine, Ain Shams University, Egypt.

Background And Study Aims: Chronic hepatitis C virus (HCV) infection has always been identified as a major health threat and a potential cause of liver cirrhosis, portal hypertension, and other associated problems. The introduction of direct-acting antiviral agents (DAAs) has represented a paradigm shift in HCV management. In this study, we aim to observe the rate of sustained virologic response (SVR12) in a large scale of patients at a single center as well as record the post-treatment changes in the hematologic, hepatic, and renal biochemical profiles. Read More

View Article and Full-Text PDF
September 2021

Transition of clinical and basic studies on liver cirrhosis treatment using cells to seek the best treatment.

Inflamm Regen 2021 Sep 16;41(1):27. Epub 2021 Sep 16.

Division of Gastroenterology and Hepatology, Graduate School of Medical and Dental Sciences, Niigata University, 1-757 Asahimachi-dori, Chuo-ku, Niigata, 951-8510, Japan.

The liver is a highly regenerative organ; however, its regeneration potential is reduced by chronic inflammation with fibrosis accumulation, leading to cirrhosis. With an aim to tackle liver cirrhosis, a life-threatening disease, trials of autologous bone marrow cell infusion (ABMi) therapy started in 2003. Clinical studies revealed that ABMi attenuated liver fibrosis and improved liver function in some patients; however, this therapy has some limitations such as the need of general anesthesia. Read More

View Article and Full-Text PDF
September 2021

A MET-agonistic antibody accelerates cirrhotic liver regeneration and improves mouse survival following partial hepatectomy.

Liver Transpl 2021 Sep 16. Epub 2021 Sep 16.

Division of Transplantation Immunology, National Research Institute for Child Health and Development, Tokyo, Japan.

Small-for-size syndrome is a common complication following partial liver transplantation and extended hepatectomy. Small-for-size syndrome is characterized by post-operative liver dysfunction caused by insufficient regenerative capacity and portal hyper-perfusion, and is more frequent in patients with pre-existing liver disease. We explored the effect of the MET-agonistic antibody 71D6 on liver regeneration and functional recovery in a mouse model of small-for-size syndrome. Read More

View Article and Full-Text PDF
September 2021